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1. Introduction 
1.1 Brain tumours/ glioma and medulloblastoma 
The total amount of brain tumours that effect humans is less than 2%. In children are brain 
tumours the second most common cancer type after leukaemia. Brain tumours and tumours 
in CNS (central nervous system) constitute 25% of all childhood tumours and is the most 
common cause of cancer mortality in children. Medulloblastoma is the most frequent 
malignant brain tumour type in children, whereas in adult glioblastoma multiforme (GBM) 
is the most malignant and common form. Although GBM occur in children but the diagnose 
is more uncommon.  
Primary brain tumours are classified according to the World Health Organization (WHO) 
which means grading (I-IV) of the tumours based on tumour histology and pathology 
(Louis, et al., 2007). However, other criteria such as the age of the patient, tumour location, 
radiological features, surgical resection, proliferation index and genetic alterations are 
important when predicting a response of therapy (Louis, et al., 2007). 
1.1.1 Glioma 
Gliomas, tumours arise from glial cells, are the most common primary brain tumours of the 
central nervous system. Gliomas can be divided into astrocytomas, oligodendrogliomas, 
oligoastrocytomas and ependymomas based on their histological pattern (Louis, et al., 2007).  
Gliomas are further divided into four clinical grades based on their histology and pathology 
where GBM is a grade IV glioma. High grade gliomas are often biphasic tumours composed 
of distinct histological parts and they contain a very heterogeneous cell population (Kattar, 
et al., 1997). GBM develops either de novo (primary GBM), or through progression of lower 
grade glioma (secondary GBM). The number of genes and chromosomal changes are often 
correlated to glioma grade. For patients diagnosed with GBM, the mean survival time is less 
than 1 year. Most gliomas diffusely infiltrate the surrounding brain tissue which makes it 
very difficult to completely eliminate the tumour and which later makes the tumour relapse 
after treatment (Louis, et al., 2007). The cell-of-origin for gliomas is still not known but the 
origin is suggested to be a glial stem-like cell or progenitor cell.  
Recently GBM is proposed to be subdivided in to four groups, classical, mesenchymal, 
proneural and neural, based on their specific gene-signature. The classical subgroup is 
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primarily characterized by EGFR (Epithelial growth factor receptor) amplification and 
expression of stem cell and neural progenitor markers. The mesenchymal group is 
distinguished with deletions in NF1 gene which results in low expression of NF1 
(Neurofibromatosis type 1) and expression of mesenchymal markers such as CHI3L1 and 
MET. GBM of proneural origin are characterized by PDGFR alterations and mutations in the 
IDH1 gene (isocitrate dehydrogenase 1). Further the proneural group express markers for 
oligodendrocytes as well as SOX genes. This group of GBM has somewhat longer survival. 
The features of the neural subgroup are expression of neural markers for instance NEFL, 
GABRA1, SYT1 and SLC12A5 (Phillips, et al., 2006; Verhaak, et al., 2010).  
1.1.2 Medulloblastoma 
Medulloblastoma is a highly invasive tumour located in the cerebellum, and belongs to the 
group of primitive neuroectodermal tumours (PNET), and generally affects children 
between three and nine years. Medulloblastoma is a grade IV tumour and the cell-of-origin 
is thought to be a pluripotent neural stem cells. Several chromosomal and genetical changes 
are identified in medulloblastoma. The most frequent change is isochromosome 17q. Other 
frequent genetical changes are affecting the Sonic hedgehog (Shh) signalling pathway, 
which are found in approximately 25% of medulloblastomas (Ellison, et al., 2003). 
Medulloblastoma is mainly divided into two subgroups, classical and desmoplastic 
medulloblastoma, and the tumour types differ in histology as well as in genetics (Ellison, et 
al., 2003). Recently medulloblastomas were subdivided into 5 different subtypes based on 
their characteristic gene-signature caused by genetic aberrations and mutations in specific 
signalling pathways as well as on their clinicopathological features (Kool, et al., 2008). The 
five subgroups are characterized by WNT-signalling (medulloblastoma type A), Shh-
signalling (type B), neuronal differentiation (type C and D) and phosphoreceptor 
differentiation (type D and E) (Kool, et al., 2008). 
A better insight and understanding of the molecular mechanisms behind infiltrative brain 
tumours and discovery of the cell-of-origin may help to generate novel ideas for treatment. 
Today treatment of brain tumours includes surgery if possible, radiation and chemotherapy 
but despite that tumours often recur and 50% of the GBM patients die within the first year 
(Holland, 2001). There have been many attempts to treat human gliomas but the success on 
the prognosis is still absent and this is mainly due to the diffuse infiltration of tumour cells 
into the normal brain tissue and unsuspected cell proliferation. Medulloblastomas are more 
sensitive to radiation and chemotherapy and about 60% are cured but many children suffer 
from severe side effects as motorical difficulties, learning problems and signs of fatigue 
(Ellison, et al., 2003).  
1.2 Cancer stem cells/ progenitor cells 
Current data suggest that initiation and progression of brain tumours are driven by cancer 
stem-like cells/progenitor cells. Cancer stem-like cells are rare tumour cells defined as cells 
which have the ability of unlimited self-renewal, the capacity to initiate and force tumour 
progression, and to differentiate into different cell lineages (Galderisi, et al., 2006). The 
cancer stem-like/progenitor cell has been identified in a number of studies of brain tumours 
(Galli, et al., 2004; Singh, et al., 2003; Yuan, et al., 2004) but exactly which cell that initially is 
transformed into the tumour initiating cell is still not clarified. Tumour progenitor cells have 
a slower division rate which could make them more resistant to treatment than the bulk 
tumour and which later can re-generate the tumour (Hirschmann-Jax, et al., 2004; G. Liu, et 
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al., 2006). Cancer stem-like cells are believed to be responsible for tumour initiation, 
progression and for tumour relapse, which make the cancer stem-like cell become a recent 
and very interesting target for novel and more effective therapies. There are many 
mechanisms involved in regulating neural stem cells and several of these seems to be 
involved in brain tumour development. To identify potential tumour stem-like cells in brain 
tumours, different neuronal precursor markers are used and further markers are used to 
study their differentiation capacity. In this chapter I will discuss certain transcription factors 
belonging to the Sox super-family. For example Sox1-4 are involved in regulating neural 
precursor cells as well as the developing CNS, these transcription factors have also recently 
been shown to be involved in the regulation of the brain tumour stem-like cell (Gangemi, et 
al., 2009; Ghods, et al., 2007; Ikushima, et al., 2009). In addition, other members of the Sox 
super-family are suggested to be involved in the differentiation process and several of the 
Sox protein family members are proposed to be used as markers for different types of brain 
tumours.  
I will discuss the new findings concerning the role of the Sox super-family in brain tumours 
and in brain tumour stem-like cells, as potential differentiation factors or as potential 
diagnostic markers of glioma but first there will be an overview of the Sox super-family and 
the normal expression of Sox proteins in the brain.    
2. The Sox super-family 
2.1 Sox structure and classification 
The first identified Sox gene was Sry, the mammalian sex-determining Y-linked gene. Sry 
contains a DNA-binding motiv known as the HMG domain (high mobility group domain) 
(Gubbay, et al., 1992; Sinclair, et al., 1990). The HMG domain is present in a number of genes 
which belongs to the HMG box super-family. The HMG domain consists of 79 amino acids 
and some of these amino acids are conserved within the HMG box super-family, although 
the HMG domains can alter to a large extent. One difference with HMG domains compare 
to other DNA-binding domains is that the HMG domains interact with the minor groove on 
the DNA helix and this binding bends the DNA drastically (for review (Wegner, 1999). The 
Sox protein family is a group of transcription factors which all contain a highly conserved 
HMG domain, the domain has more than 60% similarity to the Sry HMG domain (Sox - Sry 
related HMG box) (Laudet, et al., 1993). To date 20 different Sox genes are identified in 
humans and mice and they are divided into eight different subgroups, A-H (Table 1). 
Proteins in the same subgroup share >80% of the amino acids within the HMG domain (for 
review (Wegner, 1999). The binding properties of the HMG domains to the DNA are similar 
between the Sox proteins and the DNA sequence of recognition for binding is only 6-7 base 
pair (for review (Kamachi, et al., 2000). Except for the HMG domain, Sox proteins contain 
activating and/or repressing domains, which play a part in there transcription activity 
(Pusch, et al., 1998; van de Wetering, et al., 1993). In addition there is evidence that Sox 
proteins perform their function by a complex interplay with specific partner factors to 
regulate gene transcription. The partner factors can be different depending on cell type, 
promoter and developmental stage. This enhances the specificity of the transcriptional 
regulation by a particular Sox protein to a large extent (for review (Kamachi, et al., 2000).  
2.2 The function of Sox proteins during development and in adult 
Sox proteins are involved in several developmental and adult processes in a cell specific 
manner. A number of Sox proteins have partial overlapping expression patterns and others 
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not. Further, several of the Sox proteins have similar effects like Sox1, Sox2 and Sox3 are all 
expressed in progenitor cells during CNS development (Bylund, et al., 2003). Reduction in 
expression of one of Sox1-3 does not result in significant loss of function, e.g. deletion of 
Sox1 in mouse results in spontaneous seizures which give rise to a relatively mild CNS 
phenotype (Nishiguchi, et al., 1998) indicating that the similarities between Sox1-3 makes it 
possible for the proteins to at least some extent compensate for each other. In other cell types 
this may not be the case; for example Ferri et al show that neural precursors with deficient 
Sox2 expression in adult are dependent of correct Sox2 expression levels to generate new 
precursor cells and neurons (Ferri, et al., 2004). Sox2 is also essential in early embryonic 
development. Ablation of Sox2 in homozygous mouse case death at implantation and it is 
not even possible to generate Sox2 homozygous ES cells (Avilion, et al., 2003). Group C, 
containing Sox4, Sox11 and Sox12/22 is another group which often shows overlapping 
protein expression in both CNS and PNS (peripheral nervous system) (Cheung, et al., 2000; 
Hoser, et al., 2008).    
On the other hand the same cell type can express more than one Sox protein although the 
proteins can have counteracting effects. One example of that is the Group B of Sox genes, 
where Sox1-3, which belong to the B1 subgroup, contains an activating domain and on the 
other hand Sox14 and Sox21, subgroup B2, includes a repressive domain (Uchikawa, et al., 
1999). During embryogenesis and neurogenesis of the neural tube of chicken are genes of 
Group B1 and B2 expressed in an overlapping manner (Sandberg, et al., 2005; Uchikawa, et 
al., 1999). It is suggested that a proper balance between Group B1 and B2 proteins determine 
whether the cell stays in a progenitor/proliferating state or if the cells starts to differentiate 
(Sandberg, et al., 2005; Uchikawa, et al., 1999). It is shown that induced expression of Sox21 
in neural cells promote differentiation by disturbing the balance between Sox1-3 and Sox21 
(Sandberg, et al., 2005). Further, we have shown that an overexpression of Sox21 in glioma 
cells reduces glioma cell proliferation by inhibition of Sox2 (Ferletta, et al., 2011). 
2.3 Expression pattern of Sox proteins in the normal CNS 
The expression patterns of the different Sox proteins in brain and CNS are summarized in 
Table 1. Several of the Sox proteins are expressed during embryogenesis, one of the first is 
Sox2. Sox2 RNA is detected already at day 2.5 postcoitum (dpc) at the morula stage and 
Sox2 is shown to be important in the epiblast and the extra embryonic ectoderm as well as in 
pluripotent precursors of all embryonic and trophoblast cell types. Targed disruption of the 
Sox2 gene is embryonic lethal around implantation (Avilion, et al., 2003).  
Sox2 is important in early stages of the embryonic nervous system. In adult nervous system, 
Sox2 is mainly found in neuronal stem cells and in undifferentiated precursors (Wegner & 
Stolt, 2005) even though Sox2 is expressed in some differentiated neurons (Cavallaro, et al., 
2008). In adult is the expression of Sox2 found in the subventricular zone (SVZ) and in the 
hippocampus dentate gyrus (DG) and in these regions Sox2 is found to be co-expressed with 
GFAP and nestin and further these cells are thought to be the adult neural stem cells (Ellis, 
et al., 2004; Ferri, et al., 2004; Suh, et al., 2007). All proteins of the SoxB group (Sox1-3, Sox14 
and Sox21) are expressed in the developing brain to different extent during the development 
and many of the Sox proteins coexist throughout the CNS (Uchikawa, et al., 1999). When 
SoxB1 genes (Sox1, Sox2 or Sox3) are overexpressed in chicken neural progenitor cells, the 
cells remain in their neural progenitor state (Bylund, et al., 2003; Graham, et al., 2003).  On 
the other hand inhibition of SoxB1 proteins force cell-cycle exit and neuronal differentiation 
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(Bylund, et al., 2003). As mentioned Sox21 is able to counteract the activity of SoxB1 proteins 
and overexpression of Sox21 in chick embryos drives the neural progenitor cells to neuronal 
differentiation (Sandberg, et al., 2005).  Even though all the members of the SoxB1 genes are 
expressed in neuronal stem cells neither the Sox1 nor the Sox3 deficient mice suffer from 
sever CNS defects (Nishiguchi, et al., 1998; Weiss, et al., 2003).  
 
Sox 
subgroup 
Sox 
transcription 
factor 
Expression in CNS References: 
A SRY Midbrain and hypothalamus in adult 
male brain. 
(Lahr, et al., 1995). 
B1 SOX1 Developing CNS. Neural stem cells. 
 Adult cerebellum: Purkinje cells, 
Bergman glia.  
(Alcock, et al., 2009; Alcock & 
Sottile, 2009; Bylund, et al., 
2003; Pevny, et al., 1998; 
Uchikawa, et al., 1999). 
B1 SOX2 Developing CNS. Embryonic stem 
cells, neural stem cells.  
Adult: Neural stem cells, postmitotic 
neurons, pyramidal cells, Purkinje 
cells, Bergman glia  
(Alcock, et al., 2009; Alcock & 
Sottile, 2009; Avilion, et al., 
2003; Bylund, et al., 2003; 
Ferri, et al., 2004; Uchikawa, 
et al., 1999; Zappone, et al., 
2000). 
B1 SOX3 Developing CNS. Neural stem cells, 
mature neurons of the ventral 
hypothalamus  
(Bylund, et al., 2003; Rizzoti, 
et al., 2004; Uchikawa, et al., 
1999). 
B2 SOX14/SOX28 Developing CNS. (Uchikawa, et al., 1999). 
B2 SOX21/SOX25 Developing CNS.  (Uchikawa, et al., 1999). 
C SOX4 Developing CNS. Oligodendrocyte 
precursors, neural precursors. Early 
differentiating cells in the CNS, 
neurons. 
(Cheung, et al., 2000; 
Kuhlbrodt, Herbarth, Sock, 
Enderich, et al., 1998). 
C SOX11 Developing CNS. Oligodendrocyte 
precursors, neural precursors, mature 
neurons and later in differentiating 
brain areas as cortical plate and 
inferior colliculus.  
(Kuhlbrodt, Herbarth, Sock, 
Enderich, et al., 1998; 
Uwanogho, et al., 1995). 
C SOX12; SOX22 Developing CNS  (Jay, et al., 1997). 
D SOX5 Developing CNS, oligodendrocyte 
progenitors, oligodendrocytes and 
neuronal subpopulations (as dorsal 
horn neurons).  
Adult: oligodendrocyte progenitors  
(Stolt, et al., 2006). 
D SOX6 Developing CNS, oligodendrocyte 
progenitors, oligodendrocytes and 
neuronal subpopulations. Adult: 
oligodendrocyte progenitors  
(Connor, et al., 1995; Stolt, et 
al., 2006). 
D SOX13 Developing CNS, neural progenitors 
and in differentiating neuronal cells. 
(Y. Wang, et al., 2005). 
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Sox 
subgroup 
Sox 
transcription 
factor 
Expression in CNS References: 
E SOX8 During development of CNS in 
neurons. Oligodendrocyte precursors, 
astrocytes and oligodendrocytes. 
Immature Bergman glia and EGL cells 
(external granule layer), and 
macroglia. 
(Cheng, et al., 2001; Sock, et 
al., 2001; Stolt, et al., 2004). 
E SOX9 Neural stem cells, astrocytes, 
oligodendrocytes, Radial glia in 
developing CNS.  
Adult: neural stem cells, astrocytes 
and Bergman glia. Adult cerebellum: 
Purkinje cells  
(Alcock & Sottile, 2009; Scott, 
et al., 2010; Stolt, et al., 2003) 
(Alcock, et al., 2009). 
E SOX10 Precursor and mature 
oligodendrocytes during development 
and in adult  
(Kuhlbrodt, Herbarth, Sock, 
Hermans-Borgmeyer, et al., 
1998; Stolt, et al., 2002). 
F SOX7 Abundant expressed in the brain  (Takash, et al., 2001). 
F SOX17 No expression reported.   
F SOX18 Weak expression in brain. (Azuma, et al., 2000). 
G SOX15/SOX20
/ 
SOX26/SOX27
Embryonic stem cells  (H. J. Lee, et al., 2004; 
Maruyama, et al., 2005). 
H SOX30 Developing CNS, midbrain-hindbrain 
boundary (zebrafish)  
(De Martino, et al., 1999). 
Table 1. Sox expression in CNS. 
Sox5 and Sox6, which belong to the SoxD group, are also expressed in the developing CNS 
and are mainly found in oligodendrocyte precursors, oligodendrocytes and different types 
of neurons (Stolt, et al., 2006). Sox5 and Sox6 are primarily co-expressed, as in the 
subventricular zone, but they can be differentially expressed as in dorsal–horn neurons 
where only Sox5 is found to be expressed (Stolt, et al., 2006). Further, Stolt et al showed that 
Sox5 and Sox6 are involved in the regulation of oligodendrocyte differentiation; the 
oligodendrocytes start the terminal differentiation when Sox5 and Sox6 are downregulated. 
Mice deficient in Sox5 and Sox6 have a higher number of oligodendrocyte precursors and 
the precursors are found earlier. This is the opposite to when SoxE proteins are absent 
(Sox8-10), which results in a reduced number or lack of oligodendrocytes (Stolt, et al., 2003; 
Stolt, et al., 2005). As Sox21 can counteract the function of Sox1-3 in neural stem cells, SoxD 
proteins are suggested to counteract the function of Sox10 in oligodendrocytes (Sandberg, et 
al., 2005; Stolt, et al., 2006). Sox13, also belonging to the SoxD proteins, is likewise found 
during the development of CNS and especially during active neurogenesis. Sox13 is 
primarily suggested to participate in specification and/or differentiation of neurons and 
Sox13 is mainly found in differentiated areas and missed in the dividing ventricular zone 
(Wang, et al., 2005). Sox13 starts to be expressed in neural progenitors when the 
differentiation program is initiated (Wang, et al., 2005). Moreover, in the developing 
neocortex the expression of Sox13 is very similar to the expression of Sox4 and Sox11 in the 
primordial plexiform layer. However later during the development only Sox13 and Sox4 are 
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found in more differentiated neurons of the cortical plate and the expression of Sox11 is 
instead found in differentiating neurons of the subventricular zone (Cheung, et al., 2000; 
Uwanogho, et al., 1995; Wang, et al., 2005). 
Sox4 and Sox11, belonging to the group of SoxC proteins, are shown to have an overlapping 
expression pattern during early development of the CNS particularly in differentiating 
areas, later the expression patterns differ to a higher extent (Cheung, et al., 2000). Both Sox4 
and Sox11 are found in neural progenitors which have exited mitosis and started to 
differentiate even though expression are lost when the cells are full differentiated (Cheung, 
et al., 2000). Further, Sox4 and Sox11 are found to have comparable expression profiles in 
oligodendrocyte precursor cells and in neurons, both proteins are reduced during 
oligodendrocyte differentiation (Kuhlbrodt, Herbarth, Sock, Enderich, et al., 1998). In Sox4- 
and Sox11-null mice there were no signs of severe CNS defects even though they died 
during embryogenesis or at birth (Schilham, et al., 1996; Sock, et al., 2004). The Sox11-null 
mice die from heart defects and mutations in the Sox11 gene are suggested to be important 
in human malformation syndromes (Sock, et al., 2004). Sox12 is widely expressed both 
during embryogenesis and adulthood, and consequently expressed in the developing CNS 
with sustained expression in adult (Jay, et al., 1997). Even though Sox12 has a broad 
expression pattern is the Sox12-null mice viable and fertile and since Sox12 is expressed in 
lower levels is the overlapping expression of Sox4 and Sox11 suggested to compensate for 
the loss of Sox12 (Hoser, et al., 2008).  
In addition to the SoxC group, the SoxE group is expressed during the development of CNS 
but the expression starts just before gliogenesis. The earliest oligodendrocyte precursors in 
the CNS are developed from neuronal stem cells in the ventral ventricular zone and are 
spread from there (Pringle & Richardson, 1993). In mice, Sox9 was deleted from neural stem 
cells, which resulted in defects in the specification of oligodendrocytes and astrocytes, 
oligodendrocyte progenitors were still detected but to a much lesser extent (Stolt, et al., 
2003).  Mice deficient in both Sox8 and Sox9 failed to generate oligodendrocytes almost 
completely (Stolt, et al., 2005). In the absence of only Sox8 oligodendrocytes are generated 
normally (Stolt, et al., 2004) suggesting that lack of Sox8 can be compensated by Sox9 and 
Sox10 as well as Sox8 can compensate to same extent for the lack of Sox9 and that is why 
there still are some oligodendrocytes generated. After specification Sox10 starts to be 
expressed in the developing CNS shortly after Sox8 and Sox9 in oligodendrocyte precursors 
but in contrast to Sox8 and Sox9, is the expression of Sox10 sustained in oligodendrocytes in 
adult (Kuhlbrodt, Herbarth, Sock, Hermans-Borgmeyer, et al., 1998; Stolt, et al., 2004; Stolt, 
et al., 2002). Sox10 is shown to be important for the terminal differentiation of 
oligodendrocytes (Stolt, et al., 2002) and at this stage Sox9 is downregulated and the 
expression of Sox8 is low which makes Sox10 crucial for the terminal differentiation and the 
myelination (Stolt, et al., 2004; Stolt, et al., 2002). Sox8, Sox9 and Sox10 are not essential for 
the neuronal stem cells but they are suggested to be important in the role of altering the 
neural stem cell fate to a gliogenic fate.  
The only member of the G group is Sox15. In addition to Sox2, Sox15 is expressed in mouse 
embryonic stem cells but the mRNA is hardly detectable in the brain (Ito, 2010; H. J. Lee, et 
al., 2004; Maruyama, et al., 2005). In addition, when Sox15 is targeted disrupted the mouse is 
viable and fertile and Sox15 is suggested to have an important role in skeletal muscle 
regeneration.  
 Sox genes are expressed in different systems and in different stages both during embryonic 
development and in adult. In addition to neural development and CNS, Sox proteins are 
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reported do have important roles in lens development and in the developing PNS. Other 
important areas are cartilage development, chondrocyte development, haemopoiesis and 
sex determination (review (Wegner, 1999). Further, Sox proteins take part in several 
different cellular responses such as cell proliferation, survival, and differentiation in diverse 
cell types and tissues. Sox protein are also involved in different kinds of diseases as well as 
in cancer. In the next session the role of Sox proteins in brain tumourigenesis and especially 
the role in glioma development will be discussed.  
3. The role and expression pattern of Sox proteins in brain tumourigenesis 
Several of the Sox proteins have recently been identified in different kinds of brain tumours. 
Here I will focus on the Sox proteins which are reported to be expressed and play a role in 
brain tumourigenesis. I will mainly concentrate on the role in gliomagenesis but 
medulloblastoma and ependymoma will also be mentioned. Table 2 summaries the expression 
data reported in the literature and the IST (In Silico Transcriptomics) database is used to 
evaluate the mRNA expression of the different Sox genes in glioma (www.genesapiens.com) 
(Kilpinen, et al., 2008) and the Human protein atlas (HPA) is used to evaluate the protein 
expression (www.proteinatlas.org) (Berglund, et al., 2008; Uhlen, et al., 2005). Glioma is the 
only tumour type that is represented both in the IST and the HPA database. 
3.1 The essence of Sox2 and Sox21 in brain tumours 
There are surprisingly few reports about the role of Sox2 and Sox21 in brain tumour 
development and there are no reports about Sox1, Sox3 and Sox14, although the IST 
database tells us that Sox1 and Sox3 are expressed in glioma (Table 2).  
Considering the recent data that the tumour-initiating cell probably is a cell of immature 
nature makes Sox2 extra interesting since Sox2 is reported to be expressed in ES cells, stem 
cells and progenitor cells (as described above), both during development and adulthood 
(Ferri, et al., 2004). Further Sox2 is found in the subventricular zone of the lateral ventricles 
and in the subgranular layer of the adult hippocampus areas where brain tumours are 
thought to arise (Phi, et al., 2008; Suh, et al., 2007). All ready at an early stage we showed 
that Sox2 was expressed in different kinds of mouse glioma induced by retroviruses 
containing the PDGFB (platelet-derived growth factor B) gene (Ferletta, et al., 2007). Further, 
we and others have reported that Sox2 has a broad expression pattern in human brain 
tumours. Sox2 is found in all sorts of glioma both high and low grade as well as in 
ependymoma (Ferletta, et al., 2011; Phi, et al., 2008; Schmitz, Temme, et al., 2007). Sox2 is 
also reported to be expressed in different kinds of paediatric brain tumours such as PNET, 
medulloblastoma and glioma as well as in undifferentiated and differentiated neurospheres 
from these tumours (Ferletta, et al., 2011; Hemmati, et al., 2003; Phi, et al., 2010). The 
expression data of Sox2 in medulloblastoma is a bit contradictable. In our hands the 
medulloblastomas are positive for Sox2 expression (Ferletta, et al., 2011) but no expression is 
reported by Phi et al (Phi, et al., 2010). This discrepancy can be explained if different 
subgroups of medulloblastoma have been used. Moreover by studying paediatric tumour-
derived spheres it turned out that tumour-derived spheres were similar to normal neural 
stem cells, as they expressed the stem cell markers CD133, Musashi-1, melk, PSP, Bmi-1, 
nestin and Sox2 and the cells were able to migrate, proliferate and give rise to neurons and 
glia (Hemmati, et al., 2003), strengthening the idea that the brain tumours arise from a cell 
type of immature origin.  
www.intechopen.com
 
The Role of Sox Transcription Factors in Brain Tumourigenesis  
 
107 
Up to date there is only one report about Sox21 and brain tumours. We have shown that 
Sox21 is expressed in gliomas of different grade, ependymoma, PNET and medulloblastoma 
(Ferletta, et al., 2011) (Ferletta unpublished data). In glioma, Sox2 and Sox21 are found to be 
co-expressed in the same cell and there is a correlation between the expression of Sox2 and 
Sox21, high expression of Sox2 is associated with high expression of Sox21 (Ferletta, et al., 
2011). During development it is suggested that Sox2 and Sox21 have a counteracting activity 
(Sandberg, et al., 2005). We suggest that in brain tumour cells this fine tuning effect between 
Sox2 and Sox21 is disturbed and Sox21 is not able to inhibit the proliferation stimulated by 
Sox2. Moreover, we suggest that glioma consists of at least two cell populations: in the first 
population Sox21 is co-expressed with both Sox2 and GFAP and negative for fibronectin, the 
other cell population is instead negative for the expression of Sox2, Sox21 and GFAP but 
express fibronectin (Ferletta, et al., 2011). The co-expression of Sox2 and GFAP supports the 
idea that an adult neural stem cell in the subventricular zone could be the tumour-initiating 
cell of gliomagenesis. Also Phi et al report that Sox2 and GFAP are co-expressed in glial 
tumours of astroglial, oligodendroglial and ependymal lineages (Phi, et al., 2008). The Sox2-
/GFAP-/Sox21-/fibronectin+ population could be of a more mesenchymal phenotype 
(Rieske, et al., 2009; Tso, et al., 2006). Further, in a study of isolation and characterization of 
cancer-stem-like cells from the 9L gliosarcoma cell line, they found that the expression of 
Sox2 was turned on when the cells were cultured as spheres compared to monolayer 
cultures. The cancer stem-like cells from the spheres were able to redevelop the tumour in 
vivo with a more aggressive phenotype compared to monolayer cells and sphere forming 
cells were less susceptible to chemotherapy, this could be a result of a slower division rate 
(Ghods, et al., 2007). This even more emphasizes the importance of targeting cancer stem-
like cells to treat glioma.  
There are a few studies where Sox2 is downregulated in glioma cells. In one investigation 
Sox2 expression is diminished by microRNA in GBM tumour-initiating cells which results in 
reduced cell proliferation and that tumour cells slowly exited the cell cycle. Reduced levels 
of Sox2 further result in decreased levels of Olig2 and BF1, which are transcription factors 
that normally are expressed in neural progenitor cells. Moreover, when tumour-initiating 
cells with a silenced Sox2 were orthotopically injected into NOD/SCID mice, the cells failed 
to recapitulate the tumour compared to tumour-initiating cells that still expressed Sox2 
(Gangemi, et al., 2009). This is supported by our study showing that siRNA against Sox2 
reduces the expression of Sox2 which results in decreased cell proliferation. Reduced 
expression levels of Sox2 additionally results in decreased expression of GFAP as well as 
Sox21, further supporting the correlation between Sox2, GFAP and Sox21 (Ferletta, et al., 
2011). We have also investigated the correlation of Sox2 and Sox21 by using tetracycline 
Sox21-inducible glioma cells (by adding tetracycline Sox21 is upregulated in U-343 MGa 
Cl2.6 cells). The upregulation of Sox21 results in reduced expression of Sox2 and the cell 
proliferation was apparently decreased and this was partially a consequence of induced 
apoptosis (Ferletta, et al., 2011). During chicken development it is suggested that Sox2 and 
Sox21 must be expressed in a proper balance (Sandberg, et al., 2005; Uchikawa, et al., 1999) 
which supports our finding that when Sox21 is overexpressed are Sox2 and Sox21 able to act 
in a counteracting manner in glioma cells. From our findings we propose that Sox2 
inhibitors or Sox21 activators or proteins downstream or upstream could be potential targets 
for novel glioma therapy.  
There are a few other reports where the expression of Sox2 has been affected. Korur et al 
show that while Bmi1 is downregulated is the expression of Sox2 and nestin reduced and 
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the cells become more differentiated. Bmi1 is essential for self-renewal of neural stem cells 
and is highly expressed in GBM. In addition, while Bmi1 is reduced is the expression of 
GSK3 (glycogen synthesis kinase 3 beta) also diminished and differentiation is induced 
while proliferation, survival, migration and clonogenicity decreases (Korur, et al., 2009). 
From this the authors suggest that specific inhibitors for GSK3 or LiCl could be useful to 
downregulate Sox2 specifically and reduce the tumourigenic role of Sox2 in glioma. Further, 
Sox2 is also reported to be connected to the TGF- (transforming growth factor-) signalling 
pathway, in this study Sox2 is regulated by Sox4 (Ikushima, et al., 2009), this will be further 
mentioned in the discussion of Sox4 below.  
Yet another study shows that Sox2 is involved in self-renewal in glioma, by overexpressing 
Sox2 in glioma cells did the number and size of neurospheres increase. In addition there is a 
correlation between Sox2 expression and eIF4E (eukaryotic initiation factor 4E) in glioma 
tissue samples (Ge, et al., 2010). eIF4E is a mRNA 5’ cap-binding protein, which takes part in 
regulation of translational initiation (Richter & Sonenberg, 2005). The expression of eIF4E is 
upregulated in several kinds of cancer (Bjornsti & Houghton, 2004). In this study the authors 
suggest that eIF4E is regulating Sox2 on the protein level but not on the mRNA level and 
that the eIF4E-Sox2 affiliation could be a new potential therapeutic target (Ge, et al., 2010).  
An immunotherapy study has been performed by Schmitz et al, who first showed that Sox2 
is overexpressed in GBM. Thereafter they identified a Sox2 peptide that binds to 
immunogenic HLA-A*0201. The immunogenic HLA-A*0201-restricted peptide originated 
from Sox2 can activate tumour-directed CD8+ cytotoxic T lymphocytes (CTLs). The authors 
highlight the possible role of this Sox2-peptide in T-cell-based immunotherapy (Schmitz, 
Temme, et al., 2007).  
Moreover, there is one study of the genome-wide binding pattern for Sox2 in GBM, where  
4883 binding sites for Sox2 were identified. The expression of Sox2 in GBM was demolished 
and a microarray was performed which resulted in altered expression of 489 genes. The 
main groups of genes that were altered due to Sox2 knockdown were genes with signal 
transducer activity, transmembrane receptor genes and genes with kinase activity (Fang, et 
al., 2011). This study indicates that Sox2 probably is involved in several signalling pathways 
and cellular processes and it needs to be further investigated.   
Taken together these findings strengthen the feature of Sox2 as being important for the self-
renewal capacity and cell proliferation of neural stem cells as well as cancer stem-like cells 
and tumour cells. Several studies suggest that Sox2 or proteins up- or downstream of Sox2 
could be potential targets for brain tumour therapy. The genome-wide binding screen of 
Sox2 stressed the difficulty of finding one solution for treating glioma or identifying one 
potential target that will not be involved or be to harmful to the normal adult stem cell 
population. 
3.2 The role of Sox4 and Sox11 in glioma and medulloblastoma 
3.2.1 The role of SoxC in gliomagenesis 
Both Sox4 and Sox11 are reported to be expressed in glioma even though Sox4 mRNA 
expression was not found within the IST database (table 2). Sox11 is expressed during the 
development of CNS but in the adult brain is the expression of Sox11 downregulated. 
Compared to the adult brain Sox11 seems to be reactivated during gliomagenesis. With 
quantitative real-time PCR Sox11 is shown to be upregulated 5- to 600-fold in glioma 
(Weigle, et al., 2005). The same research group identified a ten amino-acid long peptide 
derived from Sox11 which has the ability to induce CD8+ cytotoxic T cells (CTLs) (Schmitz, 
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Wehner, et al., 2007). The Sox11 peptide was specifically expressed on glioma cells in large 
quantities and they suggest that this peptide could be suitable for T cell-based 
immunotherapy (Schmitz, Wehner, et al., 2007). Another research group confirms that Sox11 
is expressed in primary GBM (Hide, et al., 2009). Further, Hide et al establish a mouse 
glioma cell line by overexpressing HRas in p53-deficient neural stem cells and the cell line 
contained both glioma-initiating cells (GICs) and non-glioma-initiating cells (non-GICs) 
(Hide, et al., 2009). The GICs were transformed into the mouse brain and formed 
glioblastoma-like tumours. They found that the GIC did not express Sox11 compared to the 
non-GICs which still expressed Sox11. The loss of Sox11 in GICs was also confirmed in 
human GIC lines. When Sox11 was overexpressed in GICs the cells lost there tumourigenic 
ability and the cells started to differentiate towards the direction of neurons. In addition, 
when Sox11 was downregulated with short hairpin RNA in non-GICs they became 
tumourigenic (Hide, et al., 2009). Hide et al suggest that true GICs with neural stem cell 
characteristics should be negative for Sox11. Sox11 is primarily found in oligodendrocytes 
and neuronal precursors during development which fits with the finding that the GICs are 
negative for Sox11 if the tumour cell-of-origin is a neural stem cell (Kuhlbrodt, Herbarth, 
Sock, Enderich, et al., 1998; Uwanogho, et al., 1995).  
Taken together, since the expression of Sox11 seems to be high at least in primary glioma, 
Sox11 might be a target for T cell-based immunotherapy but if the GICs are negative for 
Sox11 they will escape the therapy with the risk that the relapsed tumour will be of an even 
more aggressive phenotype.  
Sox4 has in a few reports been connected to the TGF- cell signalling pathway in glioma. 
TGF- has been shown to play several roles in glioma promoting activities such as 
proliferation, invasion, metastasis and angiogenesis (review (Golestaneh & Mishra, 2005). 
The expression of Sox2 in GICs is induced by TGF- and while the TFG- signalling 
pathway is inhibited is Sox2 downregulated and the self-renewal capacity of GICs is lost 
(Ikushima, et al., 2009). In this study they propose that TGF- is not directly regulating Sox2, 
instead they found that Sox4 is a direct target of TGF- signalling. Further, Sox4 
overexpression is able to induce Sox2 expression and reduced expression of Sox4 in GICs 
results in a diminished self-renewal capacity, which suggests that Sox4 is important for 
maintaining the GICs (Ikushima, et al., 2009). On the contrary to Sox2, Sox4 is shown to be 
expressed in progenitor cells rather than in neuronal stem cells (Bylund, et al., 2003; Cheung, 
et al., 2000; Kuhlbrodt, Herbarth, Sock, Enderich, et al., 1998). The co-expression of Sox2 and 
Sox4 in glioma is supported in a DNA microarray analysis of 101 gliomas, where both Sox2 
and Sox4 are identified at high levels as well as Sox11 (Tso, et al., 2006) even though there is 
no evidence that they are expressed in the same cell. That the TGF- signalling pathway is 
mediated through Sox4 is supported by a study where the MPSS technology (massively 
parallel signature sequencing) was used on a pool of glioma tissue. Sox4 as well as TGFBI 
(transforming growth factor beta induced) were identified as alternative TGF- mediators in 
addition to SMAD mediated TGF- signalling (Lin, et al., 2010).  
3.2.2 The role of Sox4 and Sox11 in medulloblastoma 
The classical way to classify medulloblastomas are to divide them in to classical 
medulloblastoma and desmoplastic medulloblastoma (Rubinstein & Northfield, 1964). Both 
Sox4 and Sox11 are shown to be expressed in medulloblastoma and the expression pattern 
differ in the classical and the desmoplastic variants (C. J. Lee, et al., 2002). Sox4 has a strong 
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expression in all most all classical medulloblastomas and the expression is mainly found in 
undifferentiated or poorly differentiated cells. In desmoplastic medulloblastoma Sox4 
expression is weak and located to more differentiated cells (C. J. Lee, et al., 2002). In normal 
cerebellum the expression of Sox4 and Sox11 is upgregulated in granule cells that have 
stopped the proliferation and Sox4 and Sox11 are continued to be expressed in the deep 
external granular layer (EGL). As the differentiation process continues the expression of 
Sox11 is lost but the expression of Sox4 is sustained for some time (Cheung, et al., 2000). The 
expression of Sox4 in normal cerebellum fits with the expression pattern shown in 
medulloblastoma and since Sox4 is not expressed in more mature cells of the 
medulloblastoma, Sox4 is suggested to be a marker for how differentiated the tumour cells 
are (C. J. Lee, et al., 2002). Further, Sox4 and Sox11 are differentially expressed in 
medulloblastoma using microarray analysis. Sox4 was identified as a prognostic marker 
towards slightly better survival, in this study the medulloblastomas were not grouped in 
classical respectively desmoplastic medulloblastomas (de Bont, et al., 2008).  
In other tissues Sox4 is suggested to take part in apoptosis, Sox4 is reported to both induce 
apoptosis as well as stimulate anti-apoptotic activities, which effect Sox4 has is probably cell 
and tissue dependent as well as depending on which extracellular signals is reaching the cell 
(Hur, et al., 2004; P. Liu, et al., 2006). The prognosis of a desmoplastic medulloblastoma is 
somewhat better compared to classical medulloblastoma (Ellison, et al., 2003). 
To correctly classify the different medulloblastomas are important in the view of prognosis 
and better treatment. Sox4 might be a potential prognostic marker for this together with 
other cell specific markers. On the other hand Sox11 might be a prognostic marker in glioma 
connected to better survival (Hide, et al., 2009). 
3.3 The feature of SoxD proteins in glioma and medulloblastoma 
3.3.1 The role of Sox5 in gliomagenesis 
Sox5 was first reported to be involved in gliomagenesis in our retroviral insertional 
mutagenesis study in mouse. We used a retrovirus containing the PDGFB gene to tag genes 
involved in the development of malignant glioma, these brain tumour lucis can mark both 
novel or known genes (Johansson, et al., 2004). One of the tagged genes was Sox5, three 
independent proviral insertions were found in three independent tumours. The integration 
sites suggest that Sox5 expression can be upregulated or truncated which can result in a 
truncated protein or no product at all (Johansson, et al., 2004). In the follow-up study by 
Tchougonova et al, Sox5 is suggested to be a suppressor gene in PDGFB-induced gliomas 
predominantly in the Ink4a-deficient mouse background (Tchougounova, et al., 2009). In 
human glioma cell lines the expression of Sox5 was low and overexpression of Sox5 reduced 
the clone formation and the cell proliferation was inhibited. The mechanism by which Sox5 
suppresses PDGFB-induced gliomas is suggested to be due to immediate cellular senescence 
through regulation of p27Kip and Akt (Tchougounova, et al., 2009). Another report confirms 
that Sox5 expression is lower in oligodendroglial and astrocytic tumours compared to the 
already low expression in normal adult brain (Schlierf, et al., 2007). Further, it is shown that 
Sox5 contains a putative binding site for miR-21, which is a microRNA that functions as an 
anti-apoptotic factor in GBM (Chen, et al., 2008). On the contrary, another study shows that 
Sox5 has a higher expression in gliomas compared to normal brain and that about 25% of the 
glioma patients have IgG antibodies against Sox5 in there sera (Ueda, et al., 2007). The 
expression of IgG against Sox5 is preferably found in younger patients and the authors suggest 
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that the presence of IgG against Sox5 is correlated to better prognosis i.e. the survival is 
prolonged (Ueda, et al., 2007). Taken together these data propose that Sox5 expression in 
glioma could have a suppressing role in gliomagenesis and the expression of Sox5 might 
indicate a better prognosis and in that case Sox5 could be useful as a prognostic marker.  
 
Sox 
transcription 
factor 
Expression in 
brain tumour 
Reported 
expression of Sox 
mRNA in glioma 
by IST database 
Sox protein 
expression 
reported in 
glioma by the 
human protein 
atlas (HPA) 
 
References: 
IST: (Kilpinen, et 
al., 2008) 
HPA: (Berglund, 
et al., 2008; Uhlen, 
et al., 2005) 
SRY No data. No expression. No expression.  
SOX1 No data. Expressed in 
glioma. 
No data. 
 
SOX2 Glioma, 
medulloblastoma, 
PNET, 
ependymoma. 
Expressed in 
glioma. 
Expressed in all 
cases. Strong 
expression in 75% 
of the cases. 
(Ferletta, et al., 
2010; Phi, et al., 
2008) 
SOX3 No data. Expressed in 
glioma. 
No data. 
 
SOX14/SOX
28 
No data. No expression. No data. 
 
SOX21/SOX
25 
Glioma, 
medulloblastoma, 
PNET, 
ependymoma. 
Expressed in 
glioma. 
No data. 
(Ferletta, et al., 
2010) 
SOX4 Glioma, 
medulloblastoma.
No expression. Expressed in all 
cases. 
(de Bont, et al., 
2008; Ikushima, et 
al., 2009; C. J. Lee, 
et al., 2002; Lin, et 
al., 2010). 
SOX11 Glioma, 
medulloblastoma.
Expressed in 
glioma. 
Expressed with 
various intensity.
(de Bont, et al., 
2008; C. J. Lee, et 
al., 2002; Weigle, 
et al., 2005). 
SOX12; 
SOX22 
No data. No expression. No data.  
SOX5 Glioma. Expressed in 
glioma. 
No data. (Schlierf, et al., 
2007). 
SOX6 Glioma, central 
neurocytoma, 
medulloblastoma.
Expressed in 
glioma. 
Expressed in 90% 
of the cases from 
high to low levels.
(Schlierf, et al., 
2007; Ueda, 
Yoshida, et al., 
2004a, 2004b). 
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Sox 
transcription 
factor 
Expression in 
brain tumour 
Reported 
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mRNA in glioma 
by IST database 
Sox protein 
expression 
reported in 
glioma by the 
human protein 
atlas (HPA) 
 
References: 
IST: (Kilpinen, et 
al., 2008) 
HPA: (Berglund, 
et al., 2008; Uhlen, 
et al., 2005) 
SOX13 Glioma. No expression. No data. (Schlierf, et al., 
2007). 
SOX8 Glioma, 
medulloblastoma.
Expressed in 
glioma. 
No data. (Cheng, et al., 
2001; Schlierf, et 
al., 2007). 
SOX9 Glioma, 
medulloblastoma, 
ependymoma. 
Expressed in 
glioma. 
Expressed in all 
cases to varying 
extent. 
(de Bont, et al., 
2008; Kordes & 
Hagel, 2006; 
Sutter, et al., 2010) 
SOX10 Glioma, 
ependymoma. 
Expressed in 
glioma. 
Expressed in 80% 
of the cases with 
varying intensity.
(Bannykh, et al., 
2006; Ferletta, et 
al., 2007), 
SOX7 No data. No expression. Expressed but 
with different 
results. 
 
SOX17 No data. No expression. Expressed in all 
cases, high 
expression in 20% 
of the cases. 
 
SOX18 No data. No expression. No data.  
SOX15/SOX
20/ 
SOX26/SOX
27 
No data. Expressed in 
glioma. 
No data. 
 
SOX30 No data. No expression. Weak cytoplastic 
expression in 10% 
of the cases. 
 
Table 2. Reported expression of Sox proteins in different kinds of brain tumours, expression 
of Sox mRNA reported in the IST database and Sox protein expression reported in the HPA 
database. 
3.3.2 Sox6 is expressed in both medulloblastoma and glioma 
In addition to Sox5, Sox6 is reported to be expressed in glioma as well as in 
medulloblastoma and neurocytoma (Schlierf, et al., 2007; Ueda, Yoshida, et al., 2004a, 2004b) 
and the expression of Sox6 in gliomas is confirmed by the IST and HPA databases (Table 2). 
The presence of Sox6 in different kinds of glioma is slightly varying. Sox6 is reported to 
have higher mRNA expression levels in oligodendroglioma compared to astrocytomas. In 
GBM the expression levels are downregulated compared to normal adult brain and in 
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astrocytomas grade II and III are the levels slightly up- or downregulated (Schlierf, et al., 
2007). Another study showed that the Sox6 protein is expressed in GBM but not all cells are 
positive in the GBMs (Ueda, Iizuka, et al., 2004). As for Sox5 Ueda et al report that Sox6 has 
a higher expression in gliomas compared to normal brain and that one third of the patients 
develop IgG antibodies against Sox6 which is not found in the patients with other brain 
diseases or healthy persons (Ueda, Iizuka, et al., 2004). The same research group has 
continued to elucidate the possibility to vaccinate with Sox6 DNA. Glioma-bearing mice 
were vaccinated with a plasmid encoding the full-length Sox6 protein. The vaccinated mice 
developed CTLs specific for Sox6 expressing cells which resulted in a tendency of longer 
survival time compared to control mice (Ueda, et al., 2008). All though vaccination with 
Sox6 suggests an anti-tumourigenic effect, there is always a risk that the cells receiving the 
DNA transform (Munger, et al., 1989). 
3.3.3 The expression profile of Sox13 in glioma 
It is not very much known about the role of Sox13 in gliomagenesis or brain tumourigenesis. 
All though there is one report showing that the mRNA expression of Sox13 increased in 
oligodendroglioma, in astrocytomas can the expression levels be either up- or 
downregulated but in grade IV GBM is the expression mainly downregulated, all tumours 
are compared to Sox13 expression in adult brain (Schlierf, et al., 2007). 
3.4 The role of SoxE proteins in tumourigenesis 
3.4.1 The expression pattern of Sox8 in brain tumours 
Very little is known about the role of Sox8 in brain tumourigenesis. The expression of Sox8 
in gliomas is investigated by real-time RT-PCR and the expressed of Sox8 is significantly 
upregulated in most oligodendroglial tumours. The expression of Sox8 is increased in low-
grade astrocytomas, in grade III astrocytomas the expression is more heterogeneous and in 
GBM is the expression of Sox8 lower than in normal brain (Schlierf, et al., 2007). The IST 
database supports the expression of Sox8 in glioma (table 2). Moreover Sox8 is reported to 
be expressed in medulloblastoma and within medulloblastoma Sox8 is found in more 
immature cells and not in differentiated cells which fits with the normal expression of Sox8 
in microglia, oligodendrocyte progenitors as well as in EGL cells (Cheng, et al., 2001). The 
EGL cells have been suggested in several reports to be the cell-of-origin of medulloblastoma 
(Eberhart, 2007).    
3.4.2 The function of Sox9 in glioma and medulloblastoma 
Sox9 is found in both paediatric brain tumours as well as in adult brain tumours. In paediatric 
ependymoma Sox9 is predominantly overexpressed but in medulloblastoma the expression is 
reported to be low. Survival analysis showed that expression of Sox9 in ependymoma was 
associated with better overall survival (de Bont, et al., 2008). However there is another report 
indicating that Sox9 is expressed to a higher level in medulloblastoma (Kordes & Hagel, 2006). 
When studying different cell-of-origin of medulloblastoma in mice, Sox9 was identified as a 
stem cell marker on medulloblastomas arising from neural stem cells together with Sox2 and 
nestin, the expression of Sox9 or Sox2 and nestin were not found in medulloblastoma tumour 
cells originating from EGL cells. In human samples, a Sox2+ and nestin+ profile was identified 
on a subset of medulloblastoma which were more common in adult patients compared to 
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children and the profile was associated with poorer prognosis (Sutter, et al., 2010). In human 
samples the presence of Sox9 was not investigated.The conflicting data on whether Sox9 is 
expressed to a higher extent in medulloblastoma or not could be due to the fact that different 
subgroups of medulloblastoma has been studied and not mentioned and if the different 
medulloblastomas are raised from different cancer initiating cells as Sutter et al show then the 
tumours will develop in different directions. Five subgroups of medulloblastomas has been 
identified on the bases of their characteristic gene expressing profile (Kool, et al., 2008) maybe 
it is possible/necessary to subdivide them into additional and more narrowed subgroups.   
The mRNA level of Sox9 in oligodendroglial tumours is lower compared to adult brain and 
in astrocytic tumours the expression is more varying (Schlierf, et al., 2007). On the protein 
level Sox9 is found in all grades of glioma with somewhat lower expression in pilocytic 
astrocytomas (grad I) (Kordes & Hagel, 2006). The reported expression data on Sox9 match 
nicely the expression data from the IST database as well as the data from the HPA database 
(Table 2). Moreover, we have investigated the effect of overexpressing cGKII (cyclic 
guanosine monophosphate (cGMP)-dependent protein kinase II) which results in reduced 
expression of Sox9 and PDGFR and this is followed by dephosphorylation of Akt, 
suggesting a connection between Sox9, PDGFR and the Akt signalling pathway in glioma 
(Swartling, et al., 2009). The Akt signalling pathway is often activated in gliomas and the 
PDGFR is frequently constitutively activated (Nister, et al., 1988; Phillips, et al., 2006). 
Further, reduced expression of Sox9 by siRNA is decreasing the cell proliferation rate in 
glioma cells (Swartling, et al., 2009). In addition to gliomas, Sox9 is expressed in prostate 
cancers and Sox9 suppression in prostate cancer cause a downregulation of cell growth 
(Wang, et al., 2007) which support our findings in glioma. Further, overexpression of Sox9 in 
prostate cancer cells caused enhanced cell proliferation and invasion (Wang, et al., 2008). In 
prostate cancer Sox9 is suggested to be regulated by the Wnt/-catenin pathway (Wang, et 
al., 2007). The Wnt/-catenin signalling pathway is one of the characteristics of subgroup 
type A of medulloblastoma which has activated Wnt-signalling (Kool, et al., 2008). In 
prostate cancer the expression of Sox9 is higher in recurrent tumours suggesting that Sox9 is 
partially expressed by the cancer initiating cells which manage to escape the treatment 
(Wang, et al., 2007). Sox9 is expressed in neural stem cells and in progenitor cells in adult as 
well as in the embryonic CNS (Scott, et al., 2010; Stolt, et al., 2003) indicating that Sox9 could 
be important also for the brain tumour initiating cell, even though the type A subgroup 
(Wnt-signalling) of medulloblastoma has a slightly better survival rate (Kool, et al., 2008). It 
is also shown that Shh induces Sox9 during early generation of neural stem cells and that 
the expression of Sox9 is essential to keep the multipotency of the neural stem cells (Scott, et 
al., 2010), the Shh-signalling pathway is one of the activated pathways in subset B of 
medulloblastoma and is mutated in about 25% of the cases (Ellison, et al., 2003; Kool, et al., 
2008). Recurrent gliomas are often of an even more aggressive and invasive phenotype 
compared to the primary tumour supporting the finding that Sox9 could be important for 
tumour cell invasion (Wang, et al., 2008). 
3.4.3 The presence of Sox10 in glioma may indicate better prognosis  
Sox10 was first reported to be involved in gliomagenesis in our retroviral insertional 
mutagenesis study as Sox5 (Johansson, et al., 2004). Five proviral integration sites were 
identified upstream of the transcriptional start site of Sox10 and the positions of the proviral 
insertions suggests improved expression of Sox10 (Ferletta, et al., 2007; Johansson, et al., 2004). 
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Consistently with several other studies we have reported that Sox10 is expressed in both 
paediatric and adult gliomas and ependymomas with a higher expression in low grade 
tumours compared to high grade tumours (Addo-Yobo, et al., 2006; Bannykh, et al., 2006; 
Colin, et al., 2007; Ferletta, et al., 2007). On the contrary Schlierf et al found that when 
investigating the mRNA levels of Sox10 in glioma the expression levels were lower 
compared to adult brain (Schlierf, et al., 2007). The authors suggest that this could be due to 
the high expression of Sox10 in differentiated oligodendrocytes (Stolt, et al., 2002), 
meanwhile the expression in more immature oligodendrocytes are lower which is reflected 
in the tumour cells (Schlierf, et al., 2007). Further, Etcheverry et al has performed a whole-
genome integrative analysis of methylation and gene expression profiles on GBM samples 
and found that the Sox10 promoter contains two hypermethylated CpG sites which are 
related to shorter survival. However, shorter survival time is correlated with low-expression 
of Sox10 in the GBM samples (Etcheverry, et al., 2010), which fits with the expression data 
that Sox10 is expressed to a higher extent in low grade brain tumours. We and others have 
not found any expression of Sox10 in medulloblastoma (Ferletta, et al., 2007; Gershon, et al., 
2005). The lack of Sox10 in medulloblastomas may be explained by the theory that gliomas 
and medulloblastomas probably originate from different tumour-initiating cells (Marino, et 
al., 2000).   
The expression of Sox10 by itself is not enough to characterize a subgroup of gliomas as 
pilocytic astrocytomas, but together with other markers it may be possible (Colin, et al., 
2007; Rousseau, et al., 2006). Some researchers have tried to subgroup well-characterized 
gliomas depending on their expression of GFAP, vimentin, Olig2, Nkx2.2, Sox10 and nestin. 
They suggest that gliomas with strong expression of GFAP, vimentin, Olig2, Nkx2.2 and 
Sox10 can be identified as pilocytic astrocytomas, further robust expression of GFAP, 
vimentin and nestin  can categorize GBM and oligodendrogliomas can be recognized by 
Olig2 expression in almost all tumour cells while Sox10 and Nkx2.2 was found in 
subpopulations of tumour cells, these findings are not definite but may to some degree 
extend the diagnostic possibilities (Colin, et al., 2007). Moreover the study indicate how 
heterogeneous the gliomas are and emphasize the difficulties in finding treatment that will 
target all different tumour cells from the bulk cells to the tumor-initiating cells.  
There are very few reports about how Sox10 regulates/is regulated in brain tumours. Sox10 
has in pilocytic astrocytomas been correlated with high expression of ErbB3 suggesting that 
Sox10 is driving the overexpression of ErbB3 which may result in induced cell proliferation 
(Addo-Yobo, et al., 2006). This finding is supported by the knowledge that Sox10 is 
regulating ErbB3 in neural crest cells during development (Britsch, et al., 2001). Further we 
have investigated the role of Sox10 in gliomagenesis by using the RCAS/tv-a mouse model 
where a gene(s) of interest can be expressed in a specific cell type as glial progenitor cells 
(Ntv-a mice). In this study we overexpressed Sox10 alone or together with the oncogene 
PDGFB in the RCAS system. We found that Sox10 overexpression alone was not enough to 
induce any tumour formation neither in the Ntv-a wild type mice nor in the Arf-/- transgenic 
mice (Ferletta, et al., 2007). The combination of the RCAS-Sox10 virus with the RCAS-PDGFB 
virus induced glioma and the induction was four times higher with the combination 
compared to RCAS-PDGFB alone in the Arf-/- null mice. Therefore we suggest that Sox10 is 
not a potent oncogene by itself but in combination with other oncogenes as PDGFB Sox10 is 
able to increase the gliomagenicity at least in mouse (Ferletta, et al., 2007). Autocrine 
stimulation of growth factors such as PDGFA are common event in human brain tumours 
(Nistér & Westermark, 1998). Moreover, in oligodendrocyte precursors is the expression of 
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Sox10 presiding the expression of PDGFR and as soon as the expression of PDGFR is 
turned on, they are co-expressed (Stolt, et al., 2002). This supports the data that a combined 
overexpression of Sox10 and PDGFB gives raise to glioma-like tumours and that Sox10 can 
increase tumour incidence. In addition, the tumours induced with RCAS-PDGFB alone or 
together with RCAS-Sox10 both had a high expression of Sox10 suggesting that the tumour-
initiating cell is of immature origin as the oligodendrocyte precursor (Ferletta, et al., 2007) 
and this was further supported by the expression of markers for oligodendrocyte precursors 
as NG2 and PDGFR (Stallcup & Beasley, 1987) in the tumours, as well as Sox2 and nestin, 
markers for neural stem cells (Avilion, et al., 2003; Wiese, et al., 2004). 
The wide expression pattern of Sox10 in different types of human gliomas indicates that 
oligodendroglioma and astrocytoma may arise from a common tumour-initiating cell. Sox10 
does not appear to be an oncogene alone but when combined with other mutations Sox10 is 
able to increase the tumour incidence. Further, Sox10 may be used as a prognostic marker 
the presence of Sox10 is connected to better prognosis.  
4. Conclusion 
Lately there are a lot of new reports coming up about the Sox super-family and their roles in 
brain tumourigenesis, even though it is still a lot more to explore. Ten out of the 20 known 
Sox proteins are reported to be expressed in brain tumors. 
There are several discussions going on in the research field as the difference between cancer 
stem-like cells and normal neural stem cells. Sox2, Sox9 and to some extent Sox4 are shown 
to be involved in the regulation of cancer stem-like cells and the presence of these proteins 
seems to be important for the self-renewal capacity and the cell proliferation of cancer stem-
like cells. There are indications that cancer stem-like cells can escape the radiation better 
compared to the tumour bulk, this make the tumour able to relapse and often is the relapsed 
tumour even more aggressive and invasive. Specific inhibitors against Sox2, Sox9 and Sox4 
or up- or downstream targets could be of therapeutic interest if it is possible to avoid too 
much harm on the normal stem cells and the neural progenitor cells. We also show that it is 
possible to inhibit the cell proliferation induced by Sox2 with Sox21.  
In different studies specific peptides for T-cell-based immunotherapy have been made 
available for; Sox2, Sox4, Sox11, and Sox6. This needs to be further investigated, the risk 
with immunotherapy is that the cells receiving the DNA can transform and become 
tumourigenic itself. Other Sox proteins are suggested to be used as prognostic markers, as 
the expression of Sox5, Sox6, Sox4, Sox11 and Sox10 is associated with better survival. 
Unfortunately in most cases it is probably not enough with just one marker, it is a need of a 
combination of markers to get a prognostic overview of the tumours. 
Gliomas and medulloblastomas are very heterogeneous tumour types and lately they have 
been divided into different subgroups depending on their genetic background, which 
signalling pathways are activated and common genetic mutations all this to make it a little 
bit easier to find a potential target for therapy.  
Many of the Sox proteins are co-expressed in the same cell, some with interacting activity 
others with counteracting activity, but this has not been taken in to account in many of the 
reports about Sox proteins during brain tumourigenesis. Further, today there are several 
different brain tumour models in mice, both viral-induced models and transgenic models 
which can be used when studying the role of different Sox proteins during brain 
tumourigenesis to get new functional and new therapeutic ideas. 
www.intechopen.com
 
The Role of Sox Transcription Factors in Brain Tumourigenesis  
 
117 
5. Acknowledgements 
The work in the author’s laboratory is supported by grants from the Children’s Cancer 
Foundation, Åke Wibergs Foundation, Magnus Bergvalls Foundation and The Göran 
Gustafsson Foundation. 
6. References  
Addo-Yobo, S. O., Straessle, J., Anwar, A., Donson, A. M., Kleinschmidt-Demasters, B. K., & 
Foreman, N. K. (2006). Paired overexpression of ErbB3 and Sox10 in pilocytic 
astrocytoma. J Neuropathol Exp Neurol, 65(8), 769-775. 
Alcock, J., Lowe, J., England, T., Bath, P., & Sottile, V. (2009). Expression of Sox1, Sox2 and 
Sox9 is maintained in adult human cerebellar cortex. Neurosci Lett, 450(2), 114-116. 
Alcock, J., & Sottile, V. (2009). Dynamic distribution and stem cell characteristics of Sox1-
expressing cells in the cerebellar cortex. Cell Res, 19(12), 1324-1333. 
Avilion, A. A., Nicolis, S. K., Pevny, L. H., Perez, L., Vivian, N., & Lovell-Badge, R. (2003). 
Multipotent cell lineages in early mouse development depend on SOX2 function. 
Genes Dev, 17(1), 126-140. 
Azuma, T., Seki, N., Yoshikawa, T., Saito, T., Masuho, Y., & Muramatsu, M. (2000). cDNA 
cloning, tissue expression, and chromosome mapping of human homolog of 
SOX18. J Hum Genet, 45(3), 192-195. 
Bannykh, S. I., Stolt, C. C., Kim, J., Perry, A., & Wegner, M. (2006). Oligodendroglial-specific 
transcriptional factor SOX10 is ubiquitously expressed in human gliomas. J 
Neurooncol, 76(2), 115-127. 
Berglund, L., Bjorling, E., Oksvold, P., Fagerberg, L., Asplund, A., Szigyarto, C. A., et al. 
(2008). A genecentric Human Protein Atlas for expression profiles based on 
antibodies. Mol Cell Proteomics, 7(10), 2019-2027. 
Bjornsti, M. A., & Houghton, P. J. (2004). Lost in translation: dysregulation of cap-dependent 
translation and cancer. Cancer Cell, 5(6), 519-523. 
Britsch, S., Goerich, D. E., Riethmacher, D., Peirano, R. I., Rossner, M., Nave, K. A., et al. 
(2001). The transcription factor Sox10 is a key regulator of peripheral glial 
development. Genes Dev, 15(1), 66-78. 
Bylund, M., Andersson, E., Novitch, B. G., & Muhr, J. (2003). Vertebrate neurogenesis is 
counteracted by Sox1-3 activity. Nat Neurosci, 6(11), 1162-1168. 
Cavallaro, M., Mariani, J., Lancini, C., Latorre, E., Caccia, R., Gullo, F., et al. (2008). Impaired 
generation of mature neurons by neural stem cells from hypomorphic Sox2 
mutants. Development, 135(3), 541-557. 
Chen, Y., Liu, W., Chao, T., Zhang, Y., Yan, X., Gong, Y., et al. (2008). MicroRNA-21 down-
regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell 
T98G. Cancer Lett, 272(2), 197-205. 
Cheng, Y. C., Lee, C. J., Badge, R. M., Orme, A. T., & Scotting, P. J. (2001). Sox8 gene 
expression identifies immature glial cells in developing cerebellum and cerebellar 
tumours. Brain Res Mol Brain Res, 92(1-2), 193-200. 
Cheung, M., Abu-Elmagd, M., Clevers, H., & Scotting, P. J. (2000). Roles of Sox4 in central 
nervous system development. Brain Res Mol Brain Res, 79(1-2), 180-191. 
www.intechopen.com
 
Molecular Targets of CNS Tumors 
 
118 
Colin, C., Virard, I., Baeza, N., Tchoghandjian, A., Fernandez, C., Bouvier, C., et al. (2007). 
Relevance of combinatorial profiles of intermediate filaments and transcription 
factors for glioma histogenesis. Neuropathol Appl Neurobiol, 33(4), 431-439. 
Connor, F., Wright, E., Denny, P., Koopman, P., & Ashworth, A. (1995). The Sry-related 
HMG box-containing gene Sox6 is expressed in the adult testis and developing 
nervous system of the mouse. Nucleic Acids Res, 23(17), 3365-3372. 
de Bont, J. M., Kros, J. M., Passier, M. M., Reddingius, R. E., Sillevis Smitt, P. A., Luider, T. 
M., et al. (2008). Differential expression and prognostic significance of SOX genes in 
pediatric medulloblastoma and ependymoma identified by microarray analysis. 
Neuro Oncol, 10(5), 648-660. 
De Martino, S. P., Errington, F., Ashworth, A., Jowett, T., & Austin, C. A. (1999). sox30: a 
novel zebrafish sox gene expressed in a restricted manner at the midbrain-
hindbrain boundary during neurogenesis. Dev Genes Evol, 209(6), 357-362. 
Eberhart, C. G. (2007). In search of the medulloblast: neural stem cells and embryonal brain 
tumors. Neurosurg Clin N Am, 18(1), 59-69, viii-ix. 
Ellis, P., Fagan, B. M., Magness, S. T., Hutton, S., Taranova, O., Hayashi, S., et al. (2004). 
SOX2, a persistent marker for multipotential neural stem cells derived from 
embryonic stem cells, the embryo or the adult. Dev Neurosci, 26(2-4), 148-165. 
Ellison, D. W., Clifford, S. C., Gajjar, A., & Gilbertson, R. J. (2003). What's new in neuro-
oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol, 7(2), 53-66. 
Etcheverry, A., Aubry, M., de Tayrac, M., Vauleon, E., Boniface, R., Guenot, F., et al. (2010). 
DNA methylation in glioblastoma: impact on gene expression and clinical outcome. 
BMC Genomics, 11, 701. 
Fang, X., Yoon, J. G., Li, L., Yu, W., Shao, J., Hua, D., et al. (2011). The SOX2 response 
program in glioblastoma multiforme: an integrated ChIP-seq, expression 
microarray, and microRNA analysis. BMC Genomics, 12, 11. 
Ferletta, M., Caglayan, D., Mokvist, L., Jiang, Y., Kastemar, M., Uhrbom, L., et al. (2011). 
Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma 
cells. Int J Cancer, 129, 45-60. 
Ferletta, M., Uhrbom, L., Olofsson, T., Ponten, F., & Westermark, B. (2007). Sox10 has a 
broad expression pattern in gliomas and enhances platelet-derived growth factor-
B--induced gliomagenesis. Mol Cancer Res, 5(9), 891-897. 
Ferri, A. L., Cavallaro, M., Braida, D., Di Cristofano, A., Canta, A., Vezzani, A., et al. (2004). 
Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult 
mouse brain. Development, 131(15), 3805-3819. 
Galderisi, U., Cipollaro, M., & Giordano, A. (2006). Stem cells and brain cancer. Cell Death 
Differ, 13(1), 5-11. 
Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., et al. (2004). Isolation 
and characterization of tumorigenic, stem-like neural precursors from human 
glioblastoma. Cancer Res, 64(19), 7011-7021. 
Gangemi, R. M., Griffero, F., Marubbi, D., Perera, M., Capra, M. C., Malatesta, P., et al. 
(2009). SOX2 silencing in glioblastoma tumor-initiating cells causes stop of 
proliferation and loss of tumorigenicity. . Stem Cells, 27, 40-48. 
Ge, Y., Zhou, F., Chen, H., Cui, C., Liu, D., Li, Q., et al. (2010). Sox2 is translationally 
activated by eukaryotic initiation factor 4E in human glioma-initiating cells. 
Biochem Biophys Res Commun, 397(4), 711-717. 
www.intechopen.com
 
The Role of Sox Transcription Factors in Brain Tumourigenesis  
 
119 
Gershon, T. R., Oppenheimer, O., Chin, S. S., & Gerald, W. L. (2005). Temporally regulated 
neural crest transcription factors distinguish neuroectodermal tumors of varying 
malignancy and differentiation. Neoplasia, 7(6), 575-584. 
Ghods, A. J., Irvin, D., Liu, G., Yuan, X., Abdulkadir, I. R., Tunici, P., et al. (2007). Spheres 
isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive 
cancer stem-like cells. Stem Cells, 25(7), 1645-1653. 
Golestaneh, N., & Mishra, B. (2005). TGF-beta, neuronal stem cells and glioblastoma. 
Oncogene, 24(37), 5722-5730. 
Graham, V., Khudyakov, J., Ellis, P., & Pevny, L. (2003). SOX2 functions to maintain neural 
progenitor identity. Neuron, 39(5), 749-765. 
Gubbay, J., Vivian, N., Economou, A., Jackson, D., Goodfellow, P., & Lovell-Badge, R. (1992). 
Inverted repeat structure of the Sry locus in mice. Proc Natl Acad Sci U S A, 89(17), 
7953-7957. 
Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M., Geschwind, D. H., 
Bronner-Fraser, M., et al. (2003). Cancerous stem cells can arise from pediatric brain 
tumors. Proc Natl Acad Sci U S A, 100(25), 15178-15183. 
Hide, T., Takezaki, T., Nakatani, Y., Nakamura, H., Kuratsu, J., & Kondo, T. (2009). Sox11 
prevents tumorigenesis of glioma-initiating cells by inducing neuronal 
differentiation. Cancer Res, 69(20), 7953-7959. 
Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., et al. 
(2004). A distinct "side population" of cells with high drug efflux capacity in human 
tumor cells. Proc Natl Acad Sci U S A, 101(39), 14228-14233. 
Holland, E. C. (2001). Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet, 
2(2), 120-129. 
Hoser, M., Potzner, M. R., Koch, J. M., Bosl, M. R., Wegner, M., & Sock, E. (2008). Sox12 
deletion in the mouse reveals nonreciprocal redundancy with the related Sox4 and 
Sox11 transcription factors. Mol Cell Biol, 28(15), 4675-4687. 
Hur, E. H., Hur, W., Choi, J. Y., Kim, I. K., Kim, H. Y., Yoon, S. K., et al. (2004). Functional 
identification of the pro-apoptotic effector domain in human Sox4. Biochem Biophys 
Res Commun, 325(1), 59-67. 
Ikushima, H., Todo, T., Ino, Y., Takahashi, M., Miyazawa, K., & Miyazono, K. (2009). 
Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells 
through Sry-related HMG-box factors. Cell Stem Cell, 5(5), 504-514. 
Ito, M. (2010). Function and molecular evolution of mammalian Sox15, a singleton in the 
SoxG group of transcription factors. Int J Biochem Cell Biol, 42(3), 449-452. 
Jay, P., Sahly, I., Goze, C., Taviaux, S., Poulat, F., Couly, G., et al. (1997). SOX22 is a new 
member of the SOX gene family, mainly expressed in human nervous tissue. Hum 
Mol Genet, 6(7), 1069-1077. 
Johansson, F. K., Brodd, J., Eklöf, C., Ferletta, M., Hesselager, G., Tiger, C. F., et al. (2004). 
Identification of candidate cancer-causing genes in mouse brain tumors by 
retroviral tagging. PNAS, 101(31), 11334-11337. 
Kamachi, Y., Uchikawa, M., & Kondoh, H. (2000). Pairing SOX off: with partners in the 
regulation of embryonic development. Trends Genet, 16(4), 182-187. 
Kattar, M. M., Kupsky, W. J., Shimoyama, R. K., Vo, T. D., Olson, M. W., Bargar, G. R., et al. 
(1997). Clonal analysis of gliomas. Hum Pathol, 28(10), 1166-1179. 
www.intechopen.com
 
Molecular Targets of CNS Tumors 
 
120 
Kilpinen, S., Autio, R., Ojala, K., Iljin, K., Bucher, E., Sara, H., et al. (2008). Systematic 
bioinformatic analysis of expression levels of 17,330 human genes across 9,783 
samples from 175 types of healthy and pathological tissues. Genome Biol, 9(9), R139. 
Kool, M., Koster, J., Bunt, J., Hasselt, N. E., Lakeman, A., van Sluis, P., et al. (2008). 
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic 
profiles, pathway signatures and clinicopathological features. PLoS One, 3(8), e3088. 
Kordes, U., & Hagel, C. (2006). Expression of SOX9 and SOX10 in central neuroepithelial 
tumor. J Neurooncol, 80(2), 151-155. 
Korur, S., Huber, R. M., Sivasankaran, B., Petrich, M., Morin, P., Jr., Hemmings, B. A., et al. 
(2009). GSK3beta regulates differentiation and growth arrest in glioblastoma. PLoS 
One, 4(10), e7443. 
Kuhlbrodt, K., Herbarth, B., Sock, E., Enderich, J., Hermans-Borgmeyer, I., & Wegner, M. 
(1998). Cooperative function of POU proteins and SOX proteins in glial cells. J Biol 
Chem, 273(26), 16050-16057. 
Kuhlbrodt, K., Herbarth, B., Sock, E., Hermans-Borgmeyer, I., & Wegner, M. (1998). Sox10, a 
novel transcriptional modulator in glial cells. J. Neuro. sci., 18(1), 237-250. 
Lahr, G., Maxson, S. C., Mayer, A., Just, W., Pilgrim, C., & Reisert, I. (1995). Transcription of 
the Y chromosomal gene, Sry, in adult mouse brain. Brain Res Mol Brain Res, 33(1), 
179-182. 
Laudet, V., Stehelin, D., & Clevers, H. (1993). Ancestry and diversity of the HMG box 
superfamily. Nucleic Acids Res, 21(10), 2493-2501. 
Lee, C. J., Appleby, V. J., Orme, A. T., Chan, W. I., & Scotting, P. J. (2002). Differential 
expression of SOX4 and SOX11 in medulloblastoma. J Neurooncol, 57(3), 201-214. 
Lee, H. J., Goring, W., Ochs, M., Muhlfeld, C., Steding, G., Paprotta, I., et al. (2004). Sox15 is 
required for skeletal muscle regeneration. Mol Cell Biol, 24(19), 8428-8436. 
Lin, B., Madan, A., Yoon, J. G., Fang, X., Yan, X., Kim, T. K., et al. (2010). Massively parallel 
signature sequencing and bioinformatics analysis identifies up-regulation of TGFBI 
and SOX4 in human glioblastoma. PLoS One, 5(4), e10210. 
Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I. R., et al. (2006). Analysis of gene 
expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol 
Cancer, 5, 67. 
Liu, P., Ramachandran, S., Ali Seyed, M., Scharer, C. D., Laycock, N., Dalton, W. B., et al. 
(2006). Sex-determining region Y box 4 is a transforming oncogene in human 
prostate cancer cells. Cancer Res, 66(8), 4011-4019. 
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., et al. 
(2007). The 2007 WHO classification of tumours of the central nervous system. Acta 
Neuropathol, 114(2), 97-109. 
Marino, S., Vooijs, M., van Der Gulden, H., Jonkers, J., & Berns, A. (2000). Induction of 
medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the 
external granular layer cells of the cerebellum. Genes Dev, 14(8), 994-1004. 
Maruyama, M., Ichisaka, T., Nakagawa, M., & Yamanaka, S. (2005). Differential roles for 
Sox15 and Sox2 in transcriptional control in mouse embryonic stem cells. J Biol 
Chem, 280(26), 24371-24379. 
Munger, K., Phelps, W. C., Bubb, V., Howley, P. M., & Schlegel, R. (1989). The E6 and E7 
genes of the human papillomavirus type 16 together are necessary and sufficient 
for transformation of primary human keratinocytes. J Virol, 63(10), 4417-4421. 
www.intechopen.com
 
The Role of Sox Transcription Factors in Brain Tumourigenesis  
 
121 
Nishiguchi, S., Wood, H., Kondoh, H., Lovell-Badge, R., & Episkopou, V. (1998). Sox1 
directly regulates the gamma-crystallin genes and is essential for lens development 
in mice. Genes Dev, 12(6), 776-781. 
Nister, M., Libermann, T. A., Betsholtz, C., Pettersson, M., Claesson-Welsh, L., Heldin, C. H., 
et al. (1988). Expression of messenger RNAs for platelet-derived growth factor and 
transforming growth factor-alpha and their receptors in human malignant glioma 
cell lines. Cancer Res, 48(14), 3910-3918. 
Nistér, M., & Westermark, B. (1998). Mechanisms of altered growth control. Growth factors. 
In: D.D. Bigner, R.E. McLendon and J.M. Bruner (eds.), Russel and Rubinstein´s 
pathology of tumors of the nervous system. Arnold , London., 1, 83-116. 
Pevny, L. H., Sockanathan, S., Placzek, M., & Lovell-Badge, R. (1998). A role for SOX1 in 
neural determination. Development, 125(10), 1967-1978. 
Phi, J. H., Kim, J. H., Eun, K. M., Wang, K. C., Park, K. H., Choi, S. A., et al. (2010). 
Upregulation of SOX2, NOTCH1, and ID1 in supratentorial primitive 
neuroectodermal tumors: a distinct differentiation pattern from that of 
medulloblastomas. J Neurosurg Pediatr, 5(6), 608-614. 
Phi, J. H., Park, S. H., Kim, S. K., Paek, S. H., Kim, J. H., Lee, Y. J., et al. (2008). Sox2 
expression in brain tumors: a reflection of the neuroglial differentiation pathway. 
Am J Surg Pathol, 32(1), 103-112. 
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., et al. (2006). 
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of 
disease progression, and resemble stages in neurogenesis. Cancer Cell, 9(3), 157-173. 
Pringle, N. P., & Richardson, W. D. (1993). A singularity of PDGF alpha-receptor expression 
in the dorsoventral axis of the neural tube may define the origin of the 
oligodendrocyte lineage. Development, 117(2), 525-533. 
Pusch, C., Hustert, E., Pfeifer, D., Sudbeck, P., Kist, R., Roe, B., et al. (1998). The 
SOX10/Sox10 gene from human and mouse: sequence, expression, and 
transactivation by the encoded HMG domain transcription factor. Hum Genet, 
103(2), 115-123. 
Richter, J. D., & Sonenberg, N. (2005). Regulation of cap-dependent translation by eIF4E 
inhibitory proteins. Nature, 433(7025), 477-480. 
Rieske, P., Golanska, E., Zakrzewska, M., Piaskowski, S., Hulas-Bigoszewska, K., 
Wolanczyk, M., et al. (2009). Arrested neural and advanced mesenchymal 
differentiation of glioblastoma cells-comparative study with neural progenitors. 
BMC Cancer, 9, 54. 
Rizzoti, K., Brunelli, S., Carmignac, D., Thomas, P. Q., Robinson, I. C., & Lovell-Badge, R. 
(2004). SOX3 is required during the formation of the hypothalamo-pituitary axis. 
Nat Genet, 36(3), 247-255. 
Rousseau, A., Nutt, C. L., Betensky, R. A., Iafrate, A. J., Han, M., Ligon, K. L., et al. (2006). 
Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: 
use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol, 65(12), 1149-
1156. 
Rubinstein, L. J., & Northfield, D. W. (1964). The Medulloblastoma and the So-Called 
"Arachnoidal Cerebellar Sarcoma". Brain, 87, 379-412. 
Sandberg, M., Kallstrom, M., & Muhr, J. (2005). Sox21 promotes the progression of 
vertebrate neurogenesis. Nat Neurosci, 8(8), 995-1001. 
www.intechopen.com
 
Molecular Targets of CNS Tumors 
 
122 
Schilham, M. W., Oosterwegel, M. A., Moerer, P., Ya, J., de Boer, P. A., van de Wetering, M., 
et al. (1996). Defects in cardiac outflow tract formation and pro-B-lymphocyte 
expansion in mice lacking Sox-4. Nature, 380(6576), 711-714. 
Schlierf, B., Friedrich, R. P., Roerig, P., Felsberg, J., Reifenberger, G., & Wegner, M. (2007). 
Expression of SoxE and SoxD genes in human gliomas. Neuropathol Appl Neurobiol, 
33(6), 621-630. 
Schmitz, M., Temme, A., Senner, V., Ebner, R., Schwind, S., Stevanovic, S., et al. (2007). 
Identification of SOX2 as a novel glioma-associated antigen and potential target for 
T cell-based immunotherapy. Br J Cancer, 96(8), 1293-1301. 
Schmitz, M., Wehner, R., Stevanovic, S., Kiessling, A., Rieger, M. A., Temme, A., et al. (2007). 
Identification of a naturally processed T cell epitope derived from the glioma-
associated protein SOX11. Cancer Lett, 245(1-2), 331-336. 
Scott, C. E., Wynn, S. L., Sesay, A., Cruz, C., Cheung, M., Gomez Gaviro, M. V., et al. (2010). 
SOX9 induces and maintains neural stem cells. Nat Neurosci, 13(10), 1181-1189. 
Sinclair, A. H., Berta, P., Palmer, M. S., Hawkins, J. R., Griffiths, B. L., Smith, M. J., et al. 
(1990). A gene from the human sex-determining region encodes a protein with 
homology to a conserved DNA-binding motif. Nature, 346(6281), 240-244. 
Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., et al. (2003). 
Identification of a cancer stem cell in human brain tumors. Cancer Res, 63(18), 5821-
5828. 
Sock, E., Rettig, S. D., Enderich, J., Bosl, M. R., Tamm, E. R., & Wegner, M. (2004). Gene 
targeting reveals a widespread role for the high-mobility-group transcription factor 
Sox11 in tissue remodeling. Mol Cell Biol, 24(15), 6635-6644. 
Sock, E., Schmidt, K., Hermanns-Borgmeyer, I., Bosl, M. R., & Wegner, M. (2001). Idiopathic 
weight reduction in mice deficient in the high-mobility-group transcription factor 
Sox8. Mol Cell Biol, 21(20), 6951-6959. 
Stallcup, W. B., & Beasley, L. (1987). Bipotential glial precursor cells of the optic nerve 
express the NG2 proteoglycan. J Neurosci, 7(9), 2737-2744. 
Stolt, C. C., Lommes, P., Friedrich, R. P., & Wegner, M. (2004). Transcription factors Sox8 
and Sox10 perform non-equivalent roles during oligodendrocyte development 
despite functional redundancy. Development, 131(10), 2349-2358. 
Stolt, C. C., Lommes, P., Sock, E., Chaboissier, M. C., Schedl, A., & Wegner, M. (2003). The 
Sox9 transcription factor determines glial fate choice in the developing spinal cord. 
Genes Dev, 17(13), 1677-1689. 
Stolt, C. C., Rehberg, S., Ader, M., Lommes, P., Riethmacher, D., Schachner, M., et al. (2002). 
Terminal differentiation of myelin-forming oligodendrocytes depends on the 
transcription factor Sox10. Genes Dev, 16(2), 165-170. 
Stolt, C. C., Schlierf, A., Lommes, P., Hillgartner, S., Werner, T., Kosian, T., et al. (2006). SoxD 
proteins influence multiple stages of oligodendrocyte development and modulate 
SoxE protein function. Dev Cell, 11(5), 697-709. 
Stolt, C. C., Schmitt, S., Lommes, P., Sock, E., & Wegner, M. (2005). Impact of transcription 
factor Sox8 on oligodendrocyte specification in the mouse embryonic spinal cord. 
Dev Biol, 281(2), 309-317. 
Suh, H., Consiglio, A., Ray, J., Sawai, T., D'Amour, K. A., & Gage, F. H. (2007). In vivo fate 
analysis reveals the multipotent and self-renewal capacities of Sox2+ neural stem 
cells in the adult hippocampus. Cell Stem Cell, 1(5), 515-528. 
www.intechopen.com
 
The Role of Sox Transcription Factors in Brain Tumourigenesis  
 
123 
Sutter, R., Shakhova, O., Bhagat, H., Behesti, H., Sutter, C., Penkar, S., et al. (2010). 
Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and 
a neural stem cell signature characterizes a subset of human medulloblastomas. 
Oncogene, 29(12), 1845-1856. 
Swartling, F. J., Ferletta, M., Kastemar, M., Weiss, W. A., & Westermark, B. (2009). Cyclic 
GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and 
Akt phosphorylation in human glioma cell lines. Oncogene, 28(35), 3121-3131. 
Takash, W., Canizares, J., Bonneaud, N., Poulat, F., Mattei, M. G., Jay, P., et al. (2001). SOX7 
transcription factor: sequence, chromosomal localisation, expression, 
transactivation and interference with Wnt signalling. Nucleic Acids Res, 29(21), 4274-
4283. 
Tchougounova, E., Jiang, Y., Brasater, D., Lindberg, N., Kastemar, M., Asplund, A., et al. 
(2009). Sox5 can suppress platelet-derived growth factor B-induced glioma 
development in Ink4a-deficient mice through induction of acute cellular 
senescence. Oncogene, 28(12), 1537-1548. 
Tso, C. L., Shintaku, P., Chen, J., Liu, Q., Liu, J., Chen, Z., et al. (2006). Primary glioblastomas 
express mesenchymal stem-like properties. Mol Cancer Res, 4(9), 607-619. 
Uchikawa, M., Kamachi, Y., & Kondoh, H. (1999). Two distinct subgroups of Group B Sox 
genes for transcriptional activators and repressors: their expression during 
embryonic organogenesis of the chicken. Mech Dev, 84(1-2), 103-120. 
Ueda, R., Iizuka, Y., Yoshida, K., Kawase, T., Kawakami, Y., & Toda, M. (2004). 
Identification of a human glioma antigen, SOX6, recognized by patients' sera. 
Oncogene, 23(7), 1420-1427. 
Ueda, R., Kinoshita, E., Ito, R., Kawase, T., Kawakami, Y., & Toda, M. (2008). Induction of 
protective and therapeutic antitumor immunity by a DNA vaccine with a glioma 
antigen, SOX6. Int J Cancer, 122(10), 2274-2279. 
Ueda, R., Yoshida, K., Kawakami, Y., Kawase, T., & Toda, M. (2004a). Expression of a 
transcriptional factor, SOX6, in human gliomas. Brain Tumor Pathol, 21(1), 35-38. 
Ueda, R., Yoshida, K., Kawakami, Y., Kawase, T., & Toda, M. (2004b). Immunohistochemical 
analysis of SOX6 expression in human brain tumors. Brain Tumor Pathol, 21(3), 117-
120. 
Ueda, R., Yoshida, K., Kawase, T., Kawakami, Y., & Toda, M. (2007). Preferential expression 
and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. Int J 
Cancer, 120(8), 1704-1711. 
Uhlen, M., Bjorling, E., Agaton, C., Szigyarto, C. A., Amini, B., Andersen, E., et al. (2005). A 
human protein atlas for normal and cancer tissues based on antibody proteomics. 
Mol Cell Proteomics, 4(12), 1920-1932. 
Uwanogho, D., Rex, M., Cartwright, E. J., Pearl, G., Healy, C., Scotting, P. J., et al. (1995). 
Embryonic expression of the chicken Sox2, Sox3 and Sox11 genes suggests an 
interactive role in neuronal development. Mech Dev, 49(1-2), 23-36. 
van de Wetering, M., Oosterwegel, M., van Norren, K., & Clevers, H. (1993). Sox-4, an Sry-
like HMG box protein, is a transcriptional activator in lymphocytes. EMBO J, 
12(10), 3847-3854. 
Wang, H., Leav, I., Ibaragi, S., Wegner, M., Hu, G. F., Lu, M. L., et al. (2008). SOX9 is 
expressed in human fetal prostate epithelium and enhances prostate cancer 
invasion. Cancer Res, 68(6), 1625-1630. 
www.intechopen.com
 
Molecular Targets of CNS Tumors 
 
124 
Wang, H., McKnight, N. C., Zhang, T., Lu, M. L., Balk, S. P., & Yuan, X. (2007). SOX9 is 
expressed in normal prostate basal cells and regulates androgen receptor 
expression in prostate cancer cells. Cancer Res, 67(2), 528-536. 
Wang, Y., Bagheri-Fam, S., & Harley, V. R. (2005). SOX13 is up-regulated in the developing 
mouse neuroepithelium and identifies a sub-population of differentiating neurons. 
Brain Res Dev Brain Res, 157(2), 201-208. 
Wegner, M. (1999). From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res, 
27(6), 1409-1420. 
Wegner, M., & Stolt, C. C. (2005). From stem cells to neurons and glia: a Soxist's view of 
neural development. Trends Neurosci, 28(11), 583-588. 
Weigle, B., Ebner, R., Temme, A., Schwind, S., Schmitz, M., Kiessling, A., et al. (2005). 
Highly specific overexpression of the transcription factor SOX11 in human 
malignant gliomas. Oncol Rep, 13(1), 139-144. 
Weiss, J., Meeks, J. J., Hurley, L., Raverot, G., Frassetto, A., & Jameson, J. L. (2003). Sox3 is 
required for gonadal function, but not sex determination, in males and females. Mol 
Cell Biol, 23(22), 8084-8091. 
Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., et al. (2010). 
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma 
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 
17(1), 98-110. 
Wiese, C., Rolletschek, A., Kania, G., Blyszczuk, P., Tarasov, K. V., Tarasova, Y., et al. (2004). 
Nestin expression--a property of multi-lineage progenitor cells? Cell Mol Life Sci, 
61(19-20), 2510-2522. 
Yuan, X., Curtin, J., Xiong, Y., Liu, G., Waschsmann-Hogiu, S., Farkas, D. L., et al. (2004). 
Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene, 23(58), 
9392-9400. 
Zappone, M. V., Galli, R., Catena, R., Meani, N., De Biasi, S., Mattei, E., et al. (2000). Sox2 
regulatory sequences direct expression of a (beta)-geo transgene to telencephalic 
neural stem cells and precursors of the mouse embryo, revealing regionalization of 
gene expression in CNS stem cells. Development, 127(11), 2367-2382. 
 
www.intechopen.com
Molecular Targets of CNS Tumors
Edited by Dr. Miklos Garami
ISBN 978-953-307-736-9
Hard cover, 674 pages
Publisher InTech
Published online 22, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Molecular Targets of CNS Tumors is a selected review of Central Nervous System (CNS) tumors with
particular emphasis on signaling pathway of the most common CNS tumor types. To develop drugs which
specifically attack the cancer cells requires an understanding of the distinct characteristics of those cells.
Additional detailed information is provided on selected signal pathways in CNS tumors.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Maria Ferletta (2011). The Role of Sox Transcription Factors in Brain Tumourigenesis, Molecular Targets of
CNS Tumors, Dr. Miklos Garami (Ed.), ISBN: 978-953-307-736-9, InTech, Available from:
http://www.intechopen.com/books/molecular-targets-of-cns-tumors/the-role-of-sox-transcription-factors-in-
brain-tumourigenesis
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
